ALFASIGMA SPA
- Country
- 🇮🇹Italy
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.alfasigma.com
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 80
- Registration Number
- NCT06865417
- Locations
- 🇧🇪
Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola, Brussels, Belgium
🇧🇪Centre Hospitalier Regional De La Citadelle, Liege, Belgium
🇧🇪Centre Hospitalier Universitaire Dinant Godinne Sainte-Elisabeth-UCL-Namur, Namur, Belgium
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 10
- Registration Number
- NCT06222034
- Locations
- 🇫🇷
CHU Amiens - Hopital Nord, Amiens Cedex 1, France
🇩🇪Children's university hospital Charité, Campus Virchow, SPZ, Berlin, Germany
🇫🇷Bicêtre University Hospital, Le Kremlin Bicêtre, France
Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 600
- Registration Number
- NCT05817942
- Locations
- 🇩🇪
Synesis GmbH, Grünwald, Bavaria, Germany
🇫🇷CHU Nantes - Hôtel Dieu, Nantes, France
🇫🇷Hôpital Saint-Louis, Paris, France
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
- Conditions
- Axial Spondyloarthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-03-27
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 495
- Registration Number
- NCT05785611
- Locations
- 🇧🇬
Medical Center Teodora, Ruse, Bulgaria
🇧🇪Cliniques Universitaires de Bruxelles Hopital Erasme, Brussels, Belgium
🇧🇪ReumaClinic, Genk, Belgium
Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
- Conditions
- Chronic Intestinal Pseudo-obstruction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 17
- Registration Number
- NCT05724069
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg Campus, Leuven, Belgium
🇮🇹Policlinico S.Orsola-Malpighi, Bologna, Italy
🇮🇹Aou Arcispedale Sant'Anna Di Cona, Cona, Italy
Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 155
- Registration Number
- NCT05323591
- Locations
- 🇫🇷
CHU Amiens Picardie site Nord, Amiens, France
🇫🇷CHU de Amiens Picardie, Amiens, France
🇫🇷Hopital Avicenne AP-HP, Bobigny, France
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 216
- Registration Number
- NCT05150587
- Locations
- 🇺🇸
Skin Care Research, Boca Raton, Florida, United States
🇺🇸Metropolis Dermatology, Los Angeles, California, United States
🇺🇸DelRicht Research, Tulsa, Oklahoma, United States
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
- First Posted Date
- 2021-05-04
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 1304
- Registration Number
- NCT04871919
- Locations
- 🇳🇱
READE, Amsterdam, Netherlands
🇩🇪Universitatsklinikum Dusseldorf, Düsseldorf, Germany
🇮🇹AOU Policlinico Vittorio Emanuele-PO San Marco, Catania, Italy
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
- Conditions
- Papulopustular Rosacea
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2019-03-11
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 236
- Registration Number
- NCT03864978
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Federico II, Napoli, Italy
🇮🇹Azienda Ospedaliera Santa Maria, Terni, Italy
🇮🇹A.O.U. Città della Salute e della Scienza, Torino, Italy
A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention
- Conditions
- Crohn Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2018-05-25
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Alfasigma S.p.A.
- Target Recruit Count
- 43
- Registration Number
- NCT03537157
- Locations
- 🇮🇹
Humanitas Clinical Research Center, Rozzano, Italy